Immunovant, Inc. Form 10-Q Summary
Business context and reporting period
Immunovant is a clinical-stage biopharmaceutical company developing IMVT-1401, a fully human anti-FcRn monoclonal antibody for IgG-mediated autoimmune diseases. The filing covers the three months ended June 30, 2020, the first quarter of fiscal 2021, with comparative results for June 30, 2019. The company has no commercial products or revenue and operates as a single reporting segment.
Key programs included Phase 2a studies in myasthenia gravis and thyroid eye disease, a Phase 2b thyroid eye disease study, and a planned or ongoing Phase 2 study in warm autoimmune hemolytic anemia.
Financial condition and operating metrics
| Metric | Three months ended June 30, 2020 | Three months ended June 30, 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $16.9 million | $18.5 million |
| General and administrative expense | $9.7 million | $1.6 million |
| Total operating expenses | $26.6 million | $20.1 million |
| Net loss | $26.7 million | $20.1 million |
| Net loss per share | $0.38 | $0.52 |
| Net cash used in operating activities | $13.8 million | $8.3 million |
At June 30, 2020, cash was $280.3 million, compared with $100.6 million at March 31, 2020. Total assets were $290.3 million, total liabilities were $22.5 million, and stockholders' equity was $267.8 million. Accumulated deficit was $117.9 million. The filing does not report funded debt outstanding at quarter-end; the company repaid a $2.9 million note payable to Roivant Sciences Ltd. during the quarter and had $0.3 million payable to Roivant at June 30, 2020.
Financing activities provided $193.6 million of cash, including approximately $131.0 million of net proceeds from an April underwritten equity offering and approximately $65.8 million from warrant exercises. Investing cash use was $0.05 million. Stock-based compensation was approximately $4.0 million during the quarter.
Material changes versus the prior comparable period
- Net loss increased by $6.6 million, or approximately 33%, to $26.7 million.
- Research and development expense declined by $1.6 million because the prior-year period included a one-time $10.0 million HanAll development and regulatory milestone expense. Excluding that milestone, current-quarter research and development expense increased by approximately $8.5 million, primarily from higher contract manufacturing and personnel costs.
- General and administrative expense increased by $8.1 million, driven by higher headcount, stock-based compensation, and public-company legal and professional fees.
- Operating cash burn increased by $5.5 million to $13.8 million.
- Shares outstanding increased materially following the April equity offering, the issuance of 10.0 million earnout shares, and warrant exercises. Shares issued increased from 56.5 million at March 31, 2020 to 81.8 million at June 30, 2020; shares outstanding were 80.9 million because 0.9 million sponsor restricted shares remained issued but unvested.
- The first earnout milestone was achieved on May 12, 2020, triggering issuance of 10.0 million common shares and vesting of 0.9 million sponsor restricted shares. The second 10.0 million-share milestone had not been met.
Guidance, outlook, risks and unusual items
Management expects existing cash as of June 30, 2020 to fund operating expenses and capital expenditures into the first half of 2022, based on current spending and timing assumptions. The company expects significant additional losses and increasing research and development spending for the foreseeable future and does not have a committed external source of funds. Current cash will not fund all development activities and any commercial launch, so additional equity, debt, collaboration or other financing will likely be required.
Management expected results from the placebo-controlled treatment phase of the ASCEND MG trial in late third quarter or early fourth quarter of calendar 2020. Results from the ASCEND GO-2 trial were still possible in the first half of calendar 2021, and results from the WAIHA trial were still possible by the end of calendar 2020, subject to updates expected in the third quarter.
COVID-19 caused variable clinical-trial disruption, including enrollment closures at some sites beginning in March 2020. The company reported no significant overall business impact through the filing date, but future effects on enrollment, trial timelines, vendors, manufacturing, supply chains and capital markets remained uncertain.
- The HanAll license requires potential future development, regulatory and sales milestone payments of up to $442.5 million, reimbursement of up to $20.0 million for certain research and development costs, and tiered royalties on net sales.
- The company depends on HanAll for core intellectual property and on third-party contract research organizations and manufacturers for clinical development and supply.
- IMVT-1401 remains unapproved and has not entered a pivotal Phase 3 trial. Regulatory approval, clinical efficacy, safety, manufacturing and commercial viability are uncertain.
- Competition includes other FcRn inhibitors and established treatments for myasthenia gravis, thyroid eye disease and warm autoimmune hemolytic anemia.
- Roivant Sciences Ltd. beneficially owned approximately 57.7% of voting power as of August 12, 2020, making Immunovant a controlled company and creating potential related-party and governance conflicts.
- There were no material legal proceedings, no off-balance-sheet arrangements, and management concluded that disclosure controls and procedures were effective as of June 30, 2020.
Investor verification checklist
- Verify the cash runway assumptions supporting funding into the first half of 2022, including projected clinical-trial spending and future financing needs.
- Track enrollment, timing and results for the ASCEND MG, GO-2 and WAIHA programs, including any continuing COVID-19 effects.
- Assess the clinical, safety, regulatory and manufacturing evidence supporting IMVT-1401 and the path toward pivotal trials and a biologics license application.
- Review dilution from the April offering, earnout shares, warrant exercises, outstanding options and the remaining 10.0 million earnout-share obligation.
- Evaluate potential HanAll milestone, research-cost reimbursement and royalty obligations, as well as the company’s ability to fund them before product revenue.
- Consider Roivant’s majority voting control, related-party service arrangements and the implications of controlled-company governance exemptions.